Profile data is unavailable for this security.
About the company
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
- Revenue in USD (TTM)237.26m
- Net income in USD-53.21m
- Incorporated2012
- Employees304.00
- LocationEvolus Inc520 Newport Center Dr Ste 1200NEWPORT BEACH 92660-7022United StatesUSA
- Phone+1 (949) 284-4555
- Fax+1 (302) 636-5454
- Websitehttps://www.evolus.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Pacira Biosciences Inc | 690.31m | 63.59m | 675.76m | 711.00 | 12.52 | 0.7684 | 4.90 | 0.9789 | 1.17 | 1.17 | 12.34 | 19.07 | 0.4329 | 1.83 | 6.77 | 970,900.10 | 3.99 | 3.35 | 4.26 | 3.98 | 74.05 | 72.63 | 9.21 | 8.57 | 5.70 | -- | 0.4013 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 728.54m | 371.00 | -- | 12.42 | -- | 5.12 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Pliant Therapeutics Inc | 0.00 | -185.41m | 760.02m | 158.00 | -- | 1.92 | -- | -- | -3.09 | -3.09 | 0.00 | 6.50 | 0.00 | -- | -- | 0.00 | -35.03 | -33.24 | -37.15 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0711 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Liquidia Corp | 14.84m | -112.11m | 832.43m | 136.00 | -- | 12.07 | -- | 56.09 | -1.57 | -1.57 | 0.2102 | 0.8208 | 0.0993 | -- | 4.04 | 109,117.60 | -75.00 | -55.02 | -87.85 | -62.69 | 69.52 | 82.18 | -755.46 | -474.59 | 5.78 | -29.47 | 0.578 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Phibro Animal Health Corp | 1.02bn | 2.42m | 897.15m | 1.94k | 372.02 | 3.50 | 23.25 | 0.8816 | 0.0595 | 0.0595 | 25.11 | 6.34 | 1.04 | 2.59 | 6.11 | 524,576.80 | 0.2473 | 3.93 | 0.3071 | 4.90 | 30.82 | 31.18 | 0.2374 | 3.77 | 1.64 | 1.76 | 0.6554 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| PetIQ Inc | 1.13bn | 13.19m | 927.49m | 1.93k | 80.96 | 3.56 | 16.47 | 0.8177 | 0.3802 | 0.3802 | 35.27 | 8.64 | 1.28 | 5.58 | 5.55 | 586,823.10 | 1.54 | -4.32 | 1.96 | -5.23 | 24.63 | 20.05 | 1.21 | -3.66 | 1.68 | 2.09 | 0.63 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Evolus Inc | 237.26m | -53.21m | 1.02bn | 304.00 | -- | 52.95 | -- | 4.31 | -0.9073 | -0.9073 | 4.02 | 0.3063 | 1.18 | 4.32 | 6.58 | 869,084.30 | -26.42 | -40.92 | -34.63 | -59.74 | 69.72 | 65.43 | -22.43 | -80.46 | 2.67 | -2.00 | 0.8623 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Innoviva Inc | 330.50m | 145.42m | 1.22bn | 112.00 | 11.82 | 1.84 | 6.60 | 3.70 | 1.65 | 1.65 | 4.15 | 10.64 | 0.2821 | 1.02 | 3.78 | 2,950,857.00 | 12.41 | 26.24 | 12.78 | 28.53 | 87.06 | -- | 44.00 | 76.84 | 11.40 | -- | 0.4019 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Tarsus Pharmaceuticals Inc | 83.37m | -150.07m | 1.24bn | 244.00 | -- | 4.91 | -- | 14.85 | -4.43 | -4.43 | 2.43 | 6.63 | 0.2947 | -- | 5.36 | 341,696.70 | -53.05 | -31.56 | -60.10 | -33.82 | 92.50 | -- | -180.00 | -242.59 | 6.99 | -- | 0.221 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Collegium Pharmaceutical Inc | 576.65m | 99.89m | 1.25bn | 197.00 | 16.88 | 5.79 | 5.13 | 2.17 | 2.30 | 2.30 | 12.43 | 6.70 | 0.5087 | 8.14 | 3.28 | 2,927,173.00 | 8.81 | 2.79 | 14.58 | 4.80 | 61.94 | 50.88 | 17.32 | 5.16 | 1.04 | 3.69 | 0.7185 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| ANI Pharmaceuticals Inc | 538.95m | 22.95m | 1.28bn | 642.00 | 51.34 | 2.82 | 15.07 | 2.38 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.31bn | 154.00 | -- | 18.68 | -- | 13.81 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.41bn | 267.00 | -- | 3.73 | -- | 23.10 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Data as of Sep 19 2024. Currency figures normalised to Evolus Inc's reporting currency: US Dollar USD
46.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Jun 2024 | 5.75m | 9.12% |
| Tang Capital Management LLCas of 30 Jun 2024 | 4.85m | 7.68% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.51m | 5.57% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 2.91m | 4.61% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.83m | 4.48% |
| Great Point Partners LLCas of 30 Jun 2024 | 2.45m | 3.89% |
| Caligan Partners LPas of 30 Jun 2024 | 2.17m | 3.44% |
| Stonepine Capital Management LLCas of 30 Jun 2024 | 1.66m | 2.63% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 1.54m | 2.44% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.41m | 2.24% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
